

Supplementary Material

Supplementary Methods

RSV and influenza testing in Japan

In Japan, RSV and influenza tests are covered by national health insurance (NHI) and most healthcare facilities use rapid antigen kit for testing. For RSV testing any of the following groups are covered under NHI: (1) outpatient infants less than 1 year of age, (2) any hospitalized child, or (3) children eligible for palivizumab (note that the test is covered by NHI if any one of these criteria applies). For influenza testing, any outpatient is covered by insurance, regardless of age.

Influenza vaccination coverage and influenza antiviral use in Japan

Influenza vaccination coverage among children in Japan is approximately 50-60%, which is similar to the United States (U.S.).^{1,2} Outpatient antiviral use for influenza is reported to be more common among young children diagnosed for influenza in Japan (approximately 80%) compared to in the U.S. (approximately 40%).^{3,4}

Database

This retrospective cohort study was conducted using data from the Medical Data Vision (MDV) database, one of the largest electronic health records databases in Japan covering approximately 450 hospitals (25% of acute care hospitals in Japan) which includes data for over 40 million people. The MDV database includes detailed data on inpatient and outpatient encounters, drugs prescribed, diagnoses, laboratory tests performed, and medical practice (e.g., date of visit, department visited) from these hospitals.

Definition of seasonality

Seasons were defined for each year based on the epidemic curves for RSV observed annually between 2011 and 2022 by the NESID. Seasons for 2011 to 2019 were defined as beginning on May 1 of each year and ending on April 30 of the following year. Due to COVID-19 pandemic, May to December for 2020 was defined as a non-epidemic period. Since RSV seasonality was irregular after 2021, 2021 and 2022 seasons were defined as January to December (note: the study period ended on July 31, 2022, so the 2022 season was only half as long as a full season).

Definition of healthy infants

Since the MDV database may over-represent individuals with comorbidities/prematurity given it is data from acute care hospitals, some analyses were also performed by restricting to a population of “healthy children” who had no claim of the select comorbidities or prematurity (described above) and no palivizumab use.

Data on COVID-19

We initially included analysis of COVID-19 as part of the study protocol. However, data on COVID-19 were excluded from the analyses as there were very few related hospitalizations (n=14) which may be because hospitalization with COVID-19 was relatively rare during the study period and these patients were concentrated in certain hospitals that had capacity to admit COVID-19 patients (e.g., pediatric COVID-19 ward). It is likely many of these hospitals were not included in the database.

References

1. Ministry of Health Labour and Welfare. About the Seasonal Influenza Vaccine for the 2023/2024 Season. <https://www.mhlw.go.jp/content/10906000/001146456.pdf>. Accessed December 23, 2023. (In Japanese)
2. Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2022–23 Influenza Season. <https://www.cdc.gov/flu/fluview/coverage-2223estimates.htm>. Accessed December 23, 2023.
3. Okubo Y, Uda K, Miyairi I. Trends in Influenza and Related Health Resource Use During 2005–2021 Among Children in Japan. *J Pediatr Infect Dis* 2023;42:648–53.
4. Antoon JW, Sarker J, Abdelaziz A, et al. Trends in outpatient influenza antiviral use among children and adolescents in the United States. *Pediatrics*. 2023;152(6):e2023061960.

Supplementary Table 1. Relevant ICD-10 codes for conditions of interest

Condition	ICD-10 codes	Detailed description
Index disease		
RSV	J12.1	Respiratory syncytial virus pneumonia
RSV	J20.5	RSV bronchitis
RSV	J21.0	RSV bronchiolitis
RSV	B34.8	RSV infection
RSV	B97.4	RSV bronchitis
Influenza	J09	Novel influenza (H1N1)
Influenza	J10.1	Influenza A/USSR
Influenza	J11.0	Influenza pneumonia
Influenza	J11.1	Influenza
Comorbidities of interest		
Down syndrome	Q90.9	
Asthma	J45.9	
Bronchitis	J40	
Congenital heart disease	I27.8, I51.0, Q20.0-5, Q20.8-Q21.4, Q21.8-Q22.6, Q22.8, Q23.0-4, Q23.8-Q24.4, Q24.5, Q24.8-9, Q25.1, Q25.3-Q264, Q26.8, Q26.9	
Bronchopulmonary dysplasia	P27.1	
Prematurity	P07.3	
Immunodeficiency	D70.0, D71.0, D72.0, D84.9, D80.0-2, D80.4, D80.5, D80.9, D81.0, D81.9, D82.0, D82.1, D82.3, D83.0, D83.9, D84.0, D84.8, D89.1, D89.8, M35.9, Z21.0, Z94.0, Z94.1, Z94.2, Z94.3, Z94.4, Z94.8	
Intellectual developmental delay	F70-F79	
Children under supportive medical care	Japanese medical segment (kubun) codes: C101-2 – C116	
Pulmonary hypoplasia	Q33.6	
Airway stenosis	J98.8	
Esophageal atresia	Q39.3	
Congenital metabolic disorders	D52.8, E55.21, E70.0, E70.1, E70.2, E70.9, E71.0, E71.1, E71.3, E72.0, E72.1, E72.2, E72.3, E72.4, E72.9, E73.0, E74.0, E74.2, E74.4, E74.8, E74.9, E75.2, E75.5, E77.0, E77.8, E77.9, E78.0, E78.9, E79.0, E79.8, E83.0, E88.0, E88.8, E88.9, G60.1, G71.3, G90.8. P09.1	
Cystic fibrosis	E84.9	
Neuromuscular disorders	G10-14, G60, G70-73, G80-83, G90-99	
Complications		
Pneumonia	A40.3, A41.9, A49.1, G00.1, I30.1, J11.0, J12.1, J12.9, J13, J14, J15.1, J15.2, J15.4, J15.6, J15.9, J18.0, J18.1, J18.8, J18.9, J20.2, J69.0, J84.1, J84.9, J85.0, J85.1, J95.8, K65.0, U07.1	
Otitis media	H65.0, H66.4, H66.0, H66.9, H65.1, H65.9, H67.0, H67.1	
Febrile seizure	R56.0	
Encephalitis or encephalopathy	G00-G09, G41	

Myocarditis	J11.8, I40.0, I40.9, I51.4
-------------	----------------------------

*ICD-10 coding limited to codes used by the Japanese healthcare system to identify the conditions of interest and are covered in the dataset

Supplementary Table 2. Baseline characteristics of all children <5 years of age who were diagnosed in the outpatient setting with RSV infection and influenza

	RSV					Influenza				
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n relative % by age group)	176,911 (100)	70,021 (39.6)	39,311 (22.2)	42,485 (24.0)	25,094 (14.2)	153,383 (100)	8,741 (5.7)	16,295 (10.6)	39,218 (25.6)	89,129 (58.1)
Sex, n (%)										
Female	79,746 (45.1)	30,989 (44.3)	17,235 (43.8)	19,506 (45.9)	12,016 (47.9)	70,589 (46.0)	3,881 (44.4)	7,476 (45.9)	18,156 (46.3)	41,076 (46.1)
Male	97,165 (54.9)	39,032 (55.7)	22,076 (56.2)	22,979 (54.1)	13,078 (52.1)	82,794 (54.0)	4,860 (55.6)	8,819 (54.1)	21,062 (53.7)	48,053 (53.9)
Age, months										
Mean (SD)	11.8 (11.6)	2.5 (1.5)	8.3 (1.7)	16.6 (3.4)	35.0 (9.2)	29.8 (16.8)	3.1 (1.4)	8.8 (1.7)	17.1 (3.4)	41.9 (10.5)
Median (IQR)	8.0 (3.0-17.0)	2.0 (1.0-4.0)	8.0 (7.0-10.0)	16.0 (14.0-19.0)	33.0 (27.0-41.0)	28.0 (15.0-45.0)	3.0 (2.0-4.0)	9.0 (7.0-10.0)	17.0 (14.0-20.0)	42.0 (33.0-51.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	4,191 (2.4)	1,344 (1.9)	877 (2.2)	1,199 (2.8)	771 (3.1)	8,308 (5.5)	198 (2.3)	600 (3.7)	1,816 (4.7)	5,694 (6.4)
2012 (May 2012 to April 2013)	8,239 (4.7)	2,985 (4.3)	2,052 (5.2)	2,022 (4.8)	1,180 (4.7)	8,619 (5.7)	312 (3.6)	721 (4.5)	1,998 (5.1)	5,588 (6.3)
2013 (May 2013 to April 2014)	11,285 (6.4)	4,545 (6.5)	2,756 (7.0)	2,559 (6.0)	1,425 (5.7)	13,432 (8.8)	523 (6.0)	1,224 (7.6)	3,334 (8.5)	8,351 (9.4)
2014 (May 2014 to April 2015)	16,909 (9.6)	6,678 (9.5)	3,946 (10.0)	3,958 (9.3)	2,327 (9.3)	18,084 (11.9)	915 (10.5)	1,754 (10.8)	4,590 (11.8)	10,825 (12.2)
2015 (May 2015 to April 2016)	18,853 (10.7)	7,362 (10.5)	4,596 (11.7)	4,433 (10.4)	2,462 (9.8)	19,960 (13.1)	858 (9.8)	2,061 (12.7)	5,055 (13.0)	11,986 (13.6)
2016 (May 2016 to April 2017)	18,242 (10.3)	7,330 (10.5)	4,351 (11.1)	4,318 (10.2)	2,243 (9.0)	18,560 (12.2)	1,096 (12.6)	2,038 (12.6)	4,978 (12.8)	10,448 (11.8)

	25,404	9,486	6,048	6,346	3,524	24,544	1,496	2,785	6,232	14,031
2017 (May 2017 to April 2018)	(14.4)	(13.6)	(15.4)	(15.0)	(14.1)	(16.1)	(17.2)	(17.2)	(16.0)	(15.9)
	23,143	9,561	5,315	5,499	2,768	22,129	1,683	2,575	5,706	12,165
2018 (May 2018 to April 2019)	(13.1)	(13.7)	(13.5)	(13.0)	(11.0)	(14.5)	(19.3)	(15.9)	(14.6)	(13.8)
	20,601	8,311	4,481	5,172	2,637	16,333	1,255	2,093	4,473	8,512
2019 (May 2019 to April 2020)	(11.7)	(11.9)	(11.4)	(12.2)	(10.5)	(10.7)	(14.4)	(12.9)	(11.5)	(9.6)
	3,896	2,583	679	475	159	411	70	78	173	90
2020 (May to December)	(2.2)	(3.7)	(1.7)	(1.1)	(0.6)	(0.3)	(0.8)	(0.5)	(0.4)	(0.1)
	21,121	7,858	3,350	5,363	4,550	1,101	171	160	441	329
2021 (January to December)	(12.0)	(11.2)	(8.5)	(12.6)	(18.2)	(0.7.0)	(2.0)	(1.0)	(1.1)	(0.4)
	4,913	1,946	838	1,105	1,024	948	146	128	223	451
2022 (January to July)	(2.8)	(2.8)	(2.1)	(2.6)	(4.1)	(0.6)	(1.7)	(0.8)	(0.6)	(0.5)

Comorbidity during baseline period, n (%)

Congenital metabolic disorder	1,382 (0.8)	492 (0.7)	374 (1)	311 (0.7)	205 (0.8)	780 (0.5)	48 (0.6)	108 (0.7)	249 (0.6)	375 (0.4)
Neuromuscular disorder	1,078 (0.6)	356 (0.5)	243 (0.6)	267 (0.6)	212 (0.8)	638 (0.4)	27 (0.3)	89 (0.6)	220 (0.6)	302 (0.3)
Cystic fibrosis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
No record of these comorbidities	144,611 (81.7)	47,061 (67.2)	33,654 (85.6)	40,077 (94.3)	23,819 (94.9)	149,947 (97.8)	8,203 (93.8)	15,318 (94.0)	38,329 (97.7)	88,097 (98.8)
Palivizumab use, n (%)										
Yes	16,940 (9.6)	12,356 (17.7)	3,265 (8.3)	1,172 (2.8)	147 (0.6)	1,131 (0.7)	146 (1.7)	404 (2.5)	487 (1.2)	94 (0.1)
No record of use	159,971 (90.4)	57,665 (82.4)	36,046 (91.7)	41,313 (97.2)	24,947 (99.4)	152,252 (99.3)	8,595 (98.3)	15,891 (97.5)	38,731 (98.8)	89,035 (99.9)
Size of healthcare facilities, n (%)										
Less than 200 beds	13,135 (7.4)	4,296 (6.1)	3,327 (8.5)	3,462 (8.2)	2,050 (8.2)	14,403 (9.4)	412 (4.7)	1,310 (8.0)	3,599 (9.2)	9,082 (10.2)
200 to 499 beds	97,448 (55.1)	35,523 (50.7)	23,038 (58.6)	24,579 (57.9)	14,308 (57.0)	95,370 (62.2)	4,694 (53.7)	9,971 (61.2)	24,243 (61.8)	56,462 (63.4)
500 or more beds	66,328 (37.5)	30,202 (43.1)	12,946 (32.9)	14,444 (34.0)	8,736 (34.8)	43,610 (28.4)	3,635 (41.6)	5,014 (30.8)	11,376 (29.0)	23,585 (26.5)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 3 Baseline characteristics of healthy children <5 years of age who were diagnosed in the outpatient setting with RSV infection and influenza

	RSV					Influenza				
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n (relative % by age group)	141,843	45,318	33,225	39,545	23,755	149,529	8,197	15,277	38,019	88,036
	(100)	(31.9)	(23.4)	(27.9)	(16.7)	(100)	(5.5)	(10.2)	(25.4)	(58.9)
Sex, n (%)										
Female	63,794	19,792	14,462	18,158	11,382	68,883	3,643	7,016	17,600	40,624
	(45.0)	(43.7)	(43.5)	(45.9)	(47.9)	(46.1)	(44.4)	(45.9)	(46.3)	(46.1)
Male	78,049	25,526	18,763	21,387	12,373	80,646	4,554	8,261	20,419	47,412
	(55.0)	(56.3)	(56.5)	(54.1)	(52.1)	(53.9)	(55.6)	(54.1)	(53.7)	(53.9)
Age, months										
Mean (SD)	13.3 (11.9)	2.7 (1.4)	8.4 (1.7)	16.6 (3.4)	35.0 (9.2)	30.1 (16.7)	3.1 (1.4)	8.8 (1.7)	17.1 (3.4)	41.9 (10.5)
Median (IQR)	10.0	3.0	8.0	16.0	33.0	29.0	3.0	9.0	17.0	42.0
	(4.0-19.0)	(2.0-4.0)	(7.0-10.0)	(14.0-19.0)	(27.0-41.0)	(15.0-45.0)	(2.0-4.0)	(7.0-10.0)	(14.0-20.0)	(33.0-51.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	3,671	1,063	801	1,101	706	8,198	191	571	1,785	5,651
	(2.6)	(2.3)	(2.4)	(2.8)	(3.0)	(5.5)	(2.3)	(3.8)	(4.7)	(6.5)
2012 (May 2012 to April 2013)	6,880	2,224	1,722	1,839	1,095	8,474	300	689	1,957	5,528
	(4.9)	(4.9)	(5.2)	(4.7)	(4.6)	(5.7)	(3.7)	(4.5)	(5.2)	(6.3)
2013 (May 2013 to April 2014)	8,962	3,161	2,199	2,290	1,312	13,133	496	1,133	3,255	8,249
	(6.3)	(7.0)	(6.6)	(5.8)	(5.5)	(8.8)	(6.1)	(7.5)	(8.6)	(9.4)
2014 (May 2014 to April 2015)	13,808	4,610	3,385	3,662	2,151	17,659	860	1,652	4,452	10,695
	(9.7)	(10.2)	(10.2)	(9.3)	(9.1)	(11.9)	(10.5)	(10.9)	(11.8)	(12.2)
2015 (May 2015 to April 2016)	15,391	5,114	3,881	4,128	2,268	19,475	803	1,923	4,908	11,841
	(10.9)	(11.3)	(11.7)	(10.4)	(9.6)	(13.1)	(9.8)	(12.7)	(13.0)	(13.6)
2016 (May 2016 to April 2017)	14,698	4,917	3,672	4,016	2,093	18,068	1,032	1,892	4,819	10,325
	(10.4)	(10.9)	(11.1)	(10.2)	(8.8)	(12.2)	(12.6)	(12.4)	(12.7)	(11.8)

	21,058	6,623	5,240	5,862	3,333	23,843	1,389	2,613	5,999	13,842
2017 (May 2017 to April 2018)	(14.9)	(14.6)	(15.8)	(14.8)	(14.0)	(16.0)	(17.0)	(17.2)	(15.9)	(15.8)
2018 (May 2018 to April 2019)	18,823	6,395	4,602	5,174	2,652	21,540	1,566	2,431	5,529	12,014
	(13.3)	(14.1)	(13.9)	(13.1)	(11.2)	(14.5)	(19.1)	(16.0)	(14.6)	(13.7)
2019 (May 2019 to April 2020)	16,484	5,130	3,916	4,888	2,550	15,880	1,182	1,966	4,322	8,410
	(11.6)	(11.3)	(11.8)	(12.4)	(10.7)	(10.7)	(14.4)	(12.9)	(11.4)	(9.6)
2020 (May to December)	1,162	363	280	376	143	376	59	66	168	83
	(0.8)	(0.8)	(0.8)	(1.0)	(0.6)	(0.3)	(0.7)	(0.4)	(0.4)	(0.1)
2021 (January to December)	17,211	4,782	2,868	5,132	4,429	1,026	162	143	413	308
	(12.1)	(10.6)	(8.6)	(13.0)	(18.7)	(0.7)	(2.0)	(0.9)	(1.1)	(0.4)
2022 (January to July)	3,587	906	638	1,043	1,000	912	140	122	214	436
	(2.5)	(2.0)	(1.9)	(2.6)	(4.2)	(0.6)	(1.7)	(0.8)	(0.6)	(0.5)
Size of healthcare facilities, n (%)										
Less than 200 beds	11,318	3,069	2,951	3,312	1,986	14,273	401	1,281	3,555	9,036
	(8.0)	(6.8)	(8.9)	(8.4)	(8.4)	(9.5)	(4.9)	(8.4)	(9.4)	(10.3)
200 to 499 beds	83,300	25,757	20,393	23,359	13,791	93,555	4,447	9,467	23,700	55,941
	(58.7)	(56.8)	(61.4)	(59.1)	(58.1)	(62.6)	(54.3)	(62.0)	(62.3)	(63.5)
500 or more beds	47,225	16,492	9,881	12,874	7,978	41,701	3,349	4,529	10,764	23,059
	(33.3)	(36.4)	(29.7)	(32.6)	(33.6)	(27.9)	(40.9)	(29.6)	(28.3)	(26.2)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 4. Baseline characteristics for healthy children hospitalized with RSV infection and influenza overall and by age categories

	RSV					Influenza				
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n (relative % by age group)	85,550	32,909	17,618	23,046	11,977	10,764	2,064	1,100	2,728	4,872
	(100)	(38.5)	(20.6)	(26.9)	(14.0)	(100)	(19.2)	(10.2)	(25.3)	(45.3)
Sex, n (%)										
Female	38,766	14,508	7,489	10,741	6,028	4,696	952	478	1,228	2,038
	(45.3)	(44.1)	(42.5)	(46.6)	(50.3)	(43.6)	(46.1)	(43.5)	(45.0)	(41.8)
Male	46,784	18,401	10,129	12,305	5,949	6,068	1,112	622	1,500	2,834
	(54.7)	(55.9)	(57.5)	(53.4)	(49.7)	(56.4)	(53.9)	(56.5)	(55.0)	(58.2)
Age, months										
Mean (SD)	11.9 (11.2)	2.5 (1.4)	8.4 (1.7)	16.7 (3.4)	33.9 (8.6)	24.2 (17.4)	2.5 (1.3)	8.6 (1.7)	17.4 (3.4)	40.7 (10.6)
Median (IQR)	9.0	2.0	8.0	16.0	31.0	21.0	2.0	9.0	17.0	40.0
	(3.0-17.0)	(1.0-4.0)	(7.0-10.0)	(14.0-19.0)	(27.0-39.0)	(9.0-38.5)	(2.0-3.0)	(7.0-10.0)	(14.0-20.0)	(31.0-50.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	1,911	684	428	530	269	353	68	36	78	171
	(2.2)	(2.1)	(2.4)	(2.3)	(2.2)	(3.3)	(3.3)	(3.3)	(2.9)	(3.5)
2012 (May 2012 to April 2013)	3,448	1,297	799	911	441	496	97	41	124	234
	(4.0)	(3.9)	(4.5)	(4.0)	(3.7)	(4.6)	(4.7)	(3.7)	(4.6)	(4.8)
2013 (May 2013 to April 2014)	4,925	2,105	1,093	1,169	558	900	141	91	216	452
	(5.8)	(6.4)	(6.2)	(5.1)	(4.7)	(8.4)	(6.8)	(8.3)	(7.9)	(9.3)
2014 (May 2014 to April 2015)	7,587	2,987	1,684	1,961	955	1,088	251	107	254	476
	(8.9)	(9.1)	(9.6)	(8.5)	(8.0)	(10.1)	(12.2)	(9.8)	(9.3)	(9.8)
2015 (May 2015 to April 2016)	8,975	3,565	1,923	2,366	1,121	1,507	225	188	384	710
	(10.5)	(10.8)	(10.9)	(10.3)	(9.4)	(14.0)	(10.9)	(17.1)	(14.1)	(14.6)
2016 (May 2016 to April 2017)	8,375	3,343	1,906	2,214	912	1,334	293	119	337	585
	(9.8)	(10.2)	(10.8)	(9.6)	(7.6)	(12.4)	(14.2)	(10.8)	(12.4)	(12.1)

	12,640	4,763	2,798	3,436	1,643	1,612	292	162	381	777
2017 (May 2017 to April 2018)	(14.8)	(14.5)	(15.9)	(14.9)	(13.7)	(15.0)	(14.2)	(14.8)	(14.0)	(16.0)
2018 (May 2018 to April 2019)	11,639	4,739	2,556	3,034	1,310	1,818	401	173	469	775
	(13.6)	(14.4)	(14.5)	(13.2)	(10.9)	(16.9)	(19.5)	(15.8)	(17.2)	(16.0)
2019 (May 2019 to April 2020)	11,031	4,107	2,252	3,217	1,455	1,608	288	177	474	669
	(12.9)	(12.5)	(12.8)	(14.0)	(12.2)	(15.0)	(14.0)	(16.1)	(17.4)	(13.8)
2020 (May to December)	711	239	151	231	90	3	1	2	0	0
	(0.8)	(0.7)	(0.9)	(1.0)	(0.8)	(0.0)	(0.0)	(0.2)	(0.0)	(0.0)
2021 (January to December)	11,924	4,261	1,671	3,341	2,651	6	1	1	3	1
	(13.9)	(13.0)	(9.5)	(14.5)	(22.1)	(0.1)	(0.0)	(0.1)	(0.1)	(0.0)
2022 (January to July)	2,328	797	346	619	566	4	1	0	3	0
	(2.7)	(2.4)	(2.0)	(2.7)	(4.7)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)
Size of healthcare facilities, n (%)										
Less than 200 beds	5,072	1,700	1,165	1,420	787	541	66	54	152	269
	(5.9)	(5.2)	(6.6)	(6.2)	(6.6)	(5.0)	(3.2)	(4.9)	(5.6)	(5.5)
200 to 499 beds	48,569	17,932	10,427	13,476	6,734	5,907	1,100	597	1,529	2,681
	(56.8)	(54.5)	(59.2)	(58.5)	(56.2)	(54.9)	(53.3)	(54.3)	(56.0)	(55.0)
500 or more beds	31,909	13,277	6,026	8,150	4,456	4,316	898	449	1,047	1,922
	(37.3)	(40.3)	(34.2)	(35.4)	(37.2)	(40.1)	(43.5)	(40.8)	(38.4)	(39.4)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 5. Distribution of infants <1 year of age who are diagnosed in the outpatient setting, who are hospitalized, who required oxygen use, or who required mechanical ventilation with RSV infection or influenza in Japan by month of age

Age (month)	0	1	2	3	4	5	6	7	8	9	10	11
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
RSV infection												
All children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	4,311 (3.9)	15,885 (14.5)	16,961 (15.5)	12,944 (11.8)	10,884 (10.0)	9,036 (8.3)	7,830 (7.2)	7,026 (6.4)	6,311 (5.8)	6,149 (5.6)	5,967 (5.5)	6,028 (5.5)
All children: Total number of hospitalized patients per age group, n (%)	1,271 (2.3)	8,223 (15.2)	9,500 (17.6)	6,901 (12.8)	5,230 (9.7)	4,148 (7.7)	3,546 (6.6)	3,362 (6.2)	2,999 (5.5)	3,023 (5.6)	2,940 (5.4)	2,957 (5.5)
All children: Total number of patient who required mechanical ventilation per age group, n (%)	71 (4.8)	454 (30.8)	326 (22.1)	131 (8.9)	94 (6.4)	79 (5.4)	55 (3.7)	60 (4.1)	52 (3.5)	54 (3.7)	50 (3.4)	46 (3.1)
Healthy children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)												
Healthy children: Total number of hospitalized patients per age group, n (%)	1,379 (1.8%)	9,044 (11.5%)	11,192 (14.2%)	9,200 (11.7%)	7,849 (10%)	6,654 (8.5%)	5,999 (7.6%)	5,759 (7.3%)	5,389 (6.9%)	5,343 (6.8%)	5,339 (6.8%)	5,396 (6.9%)
Healthy children: Total number of patient who required mechanical ventilation per age group, n (%)	1,134 (2.2%)	7,691 (15.2%)	8,894 (17.6%)	6,500 (12.9%)	4,849 (9.6%)	3,841 (7.6%)	3,269 (6.5%)	3,152 (6.2%)	2,801 (5.5%)	2,819 (5.6%)	2,801 (5.5%)	2,776 (5.5%)
All Children: Overall hospitalizations after diagnosis (n, % of outpatient diagnoses)												
Admissions within 0-6 days	570 (13.2)	3,884 (24.5)	4,477 (26.4)	3,245 (25.1)	2,449 (22.5)	1,935 (21.4)	1,659 (21.2)	1,606 (22.9)	1,416 (22.4)	1,434 (23.3)	1,381 (23.1)	1,407 (23.3)
Admissions within 0-13 days	570	3,912	4,496	3,258	2,460	1,949	1,672	1,613	1,423	1,446	1,386	1,409

	(13.2)	(24.6)	(26.5)	(25.2)	(22.6)	(21.6)	(21.4)	(23.0)	(22.5)	(23.5)	(23.2)	(23.4)
Admissions within 0-29 days	576	3,952	4,561	3,306	2,495	1,979	1,694	1,641	1,448	1,465	1,410	1,432
	(13.4)	(24.9)	(26.9)	(25.5)	(22.9)	(21.9)	(21.6)	(23.4)	(22.9)	(23.8)	(23.6)	(23.8)

Healthy Children: Overall hospitalizations

after diagnosis

(n, % of outpatient diagnoses)

Admissions within 0-6 days	541	3,699	4,267	3,100	2,297	1,813	1,562	1,541	1,338	1,346	1,323	1,333
	(39.2)	(40.9)	(38.1)	(33.7)	(29.3)	(27.2)	(26.0)	(26.8)	(24.8)	(25.2)	(24.8)	(24.7)
Admissions within 0-13 days	541	3,726	4,283	3,112	2,306	1,826	1,573	1,547	1,345	1,356	1,325	1,333
	(39.2)	(41.2)	(38.3)	(33.8)	(29.4)	(27.4)	(26.2)	(26.9)	(25.0)	(25.4)	(24.8)	(24.7)
Admissions within 0-29 days	545	3,754	4,331	3,156	2,336	1,848	1,593	1,573	1,368	1,374	1,348	1,354
	(39.5)	(41.5)	(38.7)	(34.3)	(29.8)	(27.8)	(26.6)	(27.3)	(25.4)	(25.7)	(25.2)	(25.1)

Influenza

All children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	215 (0.9)	1,178 (4.7)	1,823 (7.3)	1,908 (7.6)	1,816 (7.3)	1,801 (7.2)	2,088 (8.3)	2,315 (9.2)	2,604 (10.4)	2,934 (11.7)	3,121 (12.5)	3,233 (12.9)
All children: Total number of hospitalized patients per age group, n (%)	53 (1.6)	405 (12.2)	655 (19.7)	519 (15.6)	327 (9.8)	182 (5.5)	193 (5.8)	168 (5.0)	184 (5.5)	206 (6.2)	222 (6.7)	215 (6.5)
All children: Total number of patient who required mechanical ventilation per age group, n (%)	0 (0.0)	1 (7.7)	4 (30.8)	0 (0.0)	2 (15.4)	1 (7.7)	0 (0.0)	2 (15.4)	0 (0.0)	1 (7.7)	1 (7.7)	1 (7.7)
Healthy children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	192 (0.8%)	1,086 (4.6%)	1,723 (7.3%)	1,810 (7.7%)	1,708 (7.3%)	1,678 (7.1%)	1,949 (8.3%)	2,174 (9.3%)	2,443 (10.4%)	2,739 (11.7%)	2,944 (12.5%)	3,028 (12.9%)

Healthy children: Total number of patient who required mechanical ventilation per age group, n (%)	0 (0%)	1 (14.3%)	3 (42.9%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (14.3%)	0 (0%)	1 (14.3%)	1 (14.3%)	0 (0%)
Healthy children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	192 (0.8%)	1,086 (4.6%)	1,723 (7.3%)	1,810 (7.7%)	1,708 (7.3%)	1,678 (7.1%)	1,949 (8.3%)	2,174 (9.3%)	2,443 (10.4%)	2,739 (11.7%)	2,944 (12.5%)	3,028 (12.9%)

All Children: Overall hospitalizations after**diagnosis****(n, % of outpatient diagnoses)**

Admissions within 0-6 days	17 (7.9)	128 (10.9)	216 (11.8)	174 (9.1)	124 (6.8)	77 (4.3)	66 (3.2)	56 (2.4)	65 (2.5)	82 (2.8)	90 (2.9)	82 (2.5)
Admissions within 0-13 days	17 (7.9)	129 (11.0)	217 (11.9)	174 (9.1)	125 (6.9)	77 (4.3)	66 (3.2)	56 (2.4)	65 (2.5)	82 (2.8)	90 (2.9)	85 (2.6)
Admissions within 0-29 days	17 (7.9)	129 (11.0)	217 (11.9)	174 (9.1)	126 (6.9)	77 (4.3)	67 (3.2)	56 (2.4)	65 (2.5)	82 (2.8)	92 (2.9)	86 (2.7)

Healthy Children: Overall hospitalizations**after diagnosis****(n, % of outpatient diagnoses)**

Admissions within 0-6 days	16 (8.3)	121 (11.1)	206 (12.0)	163 (9.0)	119 (7.0)	69 (4.1)	61 (3.1)	47 (2.2)	58 (2.4)	70 (2.6)	76 (2.6)	74 (2.4)
Admissions within 0-13 days	16 (8.3)	122 (11.2)	207 (12.0)	163 (9.0)	120 (7.0)	69 (4.1)	61 (3.1)	47 (2.2)	58 (2.4)	70 (2.6)	76 (2.6)	77 (2.5)
Admissions within 0-29 days	16 (8.3)	122 (11.2)	207 (12.0)	163 (9.0)	121 (7.1)	69 (4.1)	62 (3.2)	47 (2.2)	58 (2.4)	70 (2.6)	77 (2.6)	78 (2.6)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 6. Annual number of cases by month

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2011	4	56	0.1	36	0.3	114	0.1	954	0.6
	5	44	0.0	22	0.2	92	0.1	379	0.2
	6	60	0.1	6	0.1	103	0.1	184	0.1
	7	77	0.1	1	0.0	145	0.1	50	0.0
	8	127	0.1	0	0.0	231	0.1	17	0.0
	9	178	0.2	1	0.0	398	0.2	23	0.0
	10	219	0.2	0	0.0	466	0.3	54	0.0
	11	267	0.3	9	0.1	596	0.3	164	0.1
	12	451	0.5	19	0.2	845	0.5	578	0.4
	1	252	0.3	74	0.7	550	0.3	1,937	1.3
	2	124	0.1	111	1.0	276	0.2	2,752	1.8
	3	129	0.1	77	0.7	287	0.2	1,423	0.9
2012	4	72	0.1	40	0.4	202	0.1	747	0.5
	5	52	0.1	11	0.1	117	0.1	236	0.2
	6	80	0.1	6	0.1	164	0.1	99	0.1
	7	83	0.1	4	0.0	183	0.1	114	0.1
	8	206	0.2	6	0.1	273	0.2	91	0.1
	9	354	0.4	0	0.0	1,139	0.6	74	0.0
	10	596	0.7	1	0.0	1,430	0.8	66	0.0
	11	599	0.7	4	0.0	1,291	0.7	133	0.1
	12	699	0.8	22	0.2	1,430	0.8	499	0.3
	1	401	0.4	177	1.6	887	0.5	2,753	1.8
	2	188	0.2	154	1.4	488	0.3	2,524	1.6
	3	191	0.2	84	0.8	461	0.3	1,275	0.8
2013	4	160	0.2	48	0.4	376	0.2	755	0.5
	5	132	0.1	37	0.3	297	0.2	626	0.4
	6	116	0.1	7	0.1	248	0.1	139	0.1
	7	199	0.2	1	0.0	332	0.2	58	0.0
	8	372	0.4	0	0.0	660	0.4	22	0.0
	9	651	0.7	1	0.0	1,621	0.9	19	0.0
	10	743	0.8	1	0.0	1,603	0.9	62	0.0
	11	850	0.9	8	0.1	1,733	1.0	229	0.1
	12	894	1.0	36	0.3	1,663	0.9	652	0.4
	1	542	0.6	222	2.0	1,142	0.6	2,746	1.8
	2	285	0.3	284	2.5	679	0.4	3,870	2.5
2014	3	232	0.3	212	1.9	607	0.3	2,806	1.8
	4	243	0.3	124	1.1	700	0.4	2,203	1.4
	5	204	0.2	43	0.4	540	0.3	846	0.6

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2015	6	176	0.2	9	0.1	422	0.2	240	0.2
	7	225	0.2	2	0.0	472	0.3	126	0.1
	8	379	0.4	4	0.0	689	0.4	50	0.0
	9	850	0.9	1	0.0	2,206	1.2	93	0.1
	10	937	1.0	3	0.0	1,933	1.1	140	0.1
	11	1,405	1.6	26	0.2	2,542	1.4	504	0.3
	12	1,781	2.0	210	1.9	3,307	1.9	3,406	2.2
	1	794	0.9	545	4.9	1,653	0.9	8,043	5.2
	2	467	0.5	162	1.4	1,025	0.6	2,653	1.7
	3	433	0.5	87	0.8	1,060	0.6	1,133	0.7
	4	406	0.4	50	0.4	1,060	0.6	850	0.6
	5	218	0.2	17	0.2	593	0.3	421	0.3
2016	6	240	0.3	7	0.1	523	0.3	178	0.1
	7	336	0.4	4	0.0	530	0.3	120	0.1
	8	555	0.6	2	0.0	913	0.5	82	0.1
	9	905	1.0	6	0.1	2,333	1.3	116	0.1
	10	1,322	1.5	10	0.1	2,658	1.5	257	0.2
	11	1,922	2.1	22	0.2	3,442	1.9	462	0.3
	12	2,070	2.3	43	0.4	3,611	2.0	868	0.6
	1	874	1.0	222	2.0	1,676	0.9	3,103	2.0
	2	401	0.4	689	6.2	943	0.5	7,554	4.9
	3	338	0.4	395	3.5	852	0.5	4,625	3.0
	4	351	0.4	158	1.4	779	0.4	2,174	1.4
	5	287	0.3	34	0.3	671	0.4	610	0.4
2017	6	255	0.3	4	0.0	584	0.3	141	0.1
	7	475	0.5	7	0.1	838	0.5	90	0.1
	8	671	0.7	3	0.0	1,129	0.6	75	0.0
	9	1,400	1.5	4	0.0	3,197	1.8	119	0.1
	10	1,848	2.0	24	0.2	3,456	2.0	485	0.3
	11	1,311	1.5	45	0.4	2,376	1.3	859	0.6
	12	997	1.1	133	1.2	1,906	1.1	2,094	1.4
	1	518	0.6	408	3.6	1,187	0.7	4,963	3.2
2018	2	299	0.3	375	3.4	820	0.5	4,666	3.0
	3	381	0.4	205	1.8	951	0.5	2,478	1.6
	4	484	0.5	136	1.2	1,127	0.6	1,980	1.3
	5	509	0.6	55	0.5	1,046	0.6	1,038	0.7
	6	557	0.6	16	0.1	1,004	0.6	351	0.2
	7	1,071	1.2	11	0.1	1,767	1.0	319	0.2
2019	8	2,434	2.7	20	0.2	4,025	2.3	356	0.2

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2018	9	2,781	3.1	12	0.1	5,531	3.1	431	0.3
	10	1,692	1.9	27	0.2	3,154	1.8	491	0.3
	11	1,031	1.1	53	0.5	1,979	1.1	825	0.5
	12	976	1.1	247	2.2	1,818	1.0	3,546	2.3
	1	675	0.7	600	5.4	1,464	0.8	8,322	5.4
	2	490	0.5	404	3.6	1,118	0.6	5,553	3.6
	3	581	0.6	159	1.4	1,210	0.7	2,203	1.4
	4	637	0.7	73	0.7	1,288	0.7	1,109	0.7
	5	627	0.7	21	0.2	1,217	0.7	391	0.3
	6	657	0.7	14	0.1	1,239	0.7	227	0.1
	7	1,364	1.5	8	0.1	2,245	1.3	190	0.1
	8	2,031	2.2	8	0.1	3,787	2.1	161	0.1
2019	9	2,166	2.4	6	0.1	3,989	2.3	235	0.2
	10	1,352	1.5	14	0.1	2,546	1.4	358	0.2
	11	732	0.8	28	0.3	1,485	0.8	490	0.3
	12	819	0.9	215	1.9	1,526	0.9	2,432	1.6
	1	584	0.6	1,086	9.7	1,274	0.7	11,605	7.6
	2	530	0.6	353	3.2	1,036	0.6	3,923	2.6
	3	673	0.7	74	0.7	1,265	0.7	1,093	0.7
	4	821	0.9	68	0.6	1,534	0.9	1,024	0.7
	5	597	0.7	36	0.3	1,177	0.7	706	0.5
	6	528	0.6	13	0.1	975	0.6	295	0.2
	7	1,386	1.5	12	0.1	2,418	1.4	317	0.2
	8	2,328	2.6	13	0.1	3,826	2.2	348	0.2
2020	9	2,671	3.0	51	0.5	4,241	2.4	953	0.6
	10	1,492	1.7	48	0.4	2,493	1.4	707	0.5
	11	731	0.8	92	0.8	1,384	0.8	915	0.6
	12	662	0.7	547	4.9	1,322	0.7	4,537	3.0
	1	410	0.5	663	5.9	971	0.5	5,536	3.6
	2	355	0.4	153	1.4	799	0.5	1,452	0.9
	3	276	0.3	26	0.2	634	0.4	431	0.3
	4	140	0.2	6	0.1	361	0.2	136	0.1
	5	27	0.0	1	0.0	112	0.1	33	0.0
	6	29	0.0	0	0.0	231	0.1	33	0.0
	7	68	0.1	0	0.0	697	0.4	27	0.0
	8	59	0.1	0	0.0	649	0.4	22	0.0
	9	106	0.1	1	0.0	592	0.3	29	0.0
	10	159	0.2	0	0.0	607	0.3	53	0.0
	11	172	0.2	0	0.0	521	0.3	91	0.1

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2021	12	182	0.2	1	0.0	487	0.3	123	0.1
	1	163	0.2	1	0.0	434	0.2	104	0.1
	2	228	0.3	1	0.0	417	0.2	88	0.1
	3	465	0.5	1	0.0	621	0.4	106	0.1
	4	933	1.0	1	0.0	1,265	0.7	137	0.1
	5	1,537	1.7	0	0.0	2,163	1.2	141	0.1
	6	2,348	2.6	0	0.0	3,881	2.2	144	0.1
	7	3,135	3.5	0	0.0	5,560	3.1	108	0.1
	8	1,884	2.1	0	0.0	3,451	2.0	65	0.0
	9	772	0.9	0	0.0	1,369	0.8	37	0.0
	10	326	0.4	0	0.0	726	0.4	29	0.0
	11	228	0.3	1	0.0	563	0.3	47	0.0
	12	377	0.4	1	0.0	671	0.4	95	0.1
2022	1	330	0.4	2	0.0	588	0.3	184	0.1
	2	160	0.2	0	0.0	373	0.2	149	0.1
	3	145	0.2	0	0.0	280	0.2	132	0.1
	4	81	0.1	0	0.0	213	0.1	108	0.1
	5	155	0.2	0	0.0	437	0.2	82	0.1
	6	404	0.4	0	0.0	745	0.4	60	0.0
	7	1,135	1.3	2	0.0	2,277	1.3	233	0.2

Supplementary Table 7. Baseline characteristics of children <5 years of age who are hospitalized with RSV infection by age group and COVID-19 era

	Age <6 months			Age 6-11 months			Age 1-<2- years			Age 2-<5 years		
	Pre-	During	2021	Pre-	During	2021	Pre-	During	2021	Pre-	During	2021
	COVID-	COVID-	season	COVID-	COVID-	season	COVID-	COVID-	season	COVID-	COVID-	season
	19	19		19	19		19	19		19	19	
Total number of patients per age group per time period, n (relative % by age group)	14,877	6,106	4,456	8,311	2,536	1,771	10,142	4,574	3,438	4,537	3,573	2,731
	(39.3)	(36.4)	(35.9)	(21.9)	(15.1)	(14.3)	(26.8)	(27.2)	(27.7)	(12.0)	(21.3)	(22.0)
Sex, n (%)												
Female	6,501	2,760	2,023	3,518	1,067	732	4,775	2,074	1,582	2,228	1,813	1,396
	(43.7)	(45.2)	(45.4)	(42.3)	(42.1)	(41.3)	(47.1)	(45.3)	(46.0)	(49.1)	(50.7)	(51.1)
Male	8,376	3,346	2,433	4,793	1,469	1,039	5,367	2,500	1,856	2,309	1,760	1,335
	(56.3)	(54.8)	(54.6)	(57.7)	(57.9)	(58.7)	(52.9)	(54.7)	(54.0)	(50.9)	(49.3)	(48.9)
Age, months												
Mean (SD)	2.6 (1.4)	2.4 (1.4)	2.3 (1.4)	8.4 (1.7)	8.5 (1.7)	8.4 (1.7)	16.5 (3.3)	17.3 (3.4)	17.4 (3.4)	33.7 (8.5)	34.0 (8.8)	33.8 (8.7)
Median (IQR)	2.0	2.0	2.0	8.0	8.0	8.0	16.0	17.0	17.0	31.0	31.0	31.0
	(1.0-4.0)	(1.0-3.0)	(1.0-3.0)	(7.0-10.0)	(7.0-10.0)	(7.0-10.0)	(14.0-	(14.0-	(15.0-	(27.0-	(27.0-	(27.0-
							19.0)	20.0)	20.0)	39.0)	39.0)	39.0)
Season by year, n (%)												
2016 (May 2016 to April 2017)	758	0	0	425	0	0	353	0	0	146	0	0
	(5.1)	(0.0)	(0.0)	(5.1)	(0.0)	(0.0)	(3.5)	(0.0)	(0.0)	(3.2)	(0.0)	(0.0)
2017 (May 2017 to April 2018)	5,148	0	0	2,987	0	0	3,588	0	0	1,711	0	0
	(34.6)	(0.0)	(0.0)	(35.9)	(0.0)	(0.0)	(35.4)	(0.0)	(0.0)	(37.7)	(0.0)	(0.0)
2018 (May 2018 to April 2019)	5,105	0	0	2,754	0	0	3,148	0	0	1,349	0	0
	(34.3)	(0.0)	(0.0)	(33.1)	(0.0)	(0.0)	(31.0)	(0.0)	(0.0)	(29.7)	(0.0)	(0.0)
2019 (May 2019 to April 2020)	3,866	514	0	2,145	237	0	3,053	260	0	1,331	170	0
	(26.0)	(8.4)	(0.0)	(25.8)	(9.3)	(0.0)	(30.1)	(5.7)	(0.0)	(29.3)	(4.8)	(0.0)
2020 (May to December)	0	304	0	0	166	0	0	238	0	0	94	0

	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
No record of these comorbidities	5,782	4,263	7,815	2,391	1,675	9,869	4,475	3,361	4,389	3,479	2,655
	(94.7)	(95.7)	(94.0)	(94.3)	(94.6)	(97.3)	(97.8)	(97.8)	(96.7)	(97.4)	(97.2)
Palivizumab use, n (%)											
Yes	343	95	47	211	59	38	174	52	37	15	13
	(2.3)	(1.6)	(1.1)	(2.5)	(2.3)	(2.1)	(1.7)	(1.1)	(1.1)	(0.3)	(0.4)
No record of use	14,534	6,011	4,409	8,100	2,477	1,733	9,968	4,522	3,401	4,522	3,560
	(97.7)	(98.4)	(98.9)	(97.5)	(97.7)	(97.9)	(98.3)	(98.9)	(98.9)	(99.7)	(99.6)
Size of healthcare facilities, n (%)											
Less than 200 beds	679	358	255	489	196	132	524	350	254	240	302
	(4.6)	(5.9)	(5.7)	(5.9)	(7.7)	(7.5)	(5.2)	(7.7)	(7.4)	(5.3)	(8.5)
200 to 499 beds	8,137	3,296	2,395	4,930	1,501	1,028	5,994	2,599	1,962	2,595	1,982
	(54.7)	(54.0)	(53.7)	(59.3)	(59.2)	(58.0)	(59.1)	(56.8)	(57.1)	(57.2)	(55.5)
500 or more beds	6,061	2,452	1,806	2,892	839	611	3,624	1,625	1,222	1,702	1,289
	(40.7)	(40.2)	(40.5)	(34.8)	(33.1)	(34.5)	(35.7)	(35.5)	(35.5)	(37.5)	(36.1)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 8. Baseline characteristics of children <5 years of age who are hospitalized with influenza in Japan by age group and COVID-19 era

	Age <6 months			Age 6-11 months			Age 1-<2- years			Age 2-<5 years		
	Pre-	During	2021	Pre-	During	2021	Pre-	During	2021	Pre-	During	2021
	COVID-	COVID-	season	COVID-	COVID-	season	COVID-	COVID-	season	COVID-	COVID-	season
	19	19		19	19		19	19		19	19	
Total number of patients per age group per time period, n (relative % by age group)	1,125 (20.4)	155 (18.0)	1 (16.7)	568 (10.3)	97 (11.3)	1 (16.7)	1,384 (25.1)	275 (31.9)	3 (50.0)	2,431 (44.1)	334 (38.8)	1 (16.7)
Sex, n (%)												
Female	528 (46.9)	63 (40.6)	1 (100)	260 (45.8)	38 (39.2)	1 (100)	620 (44.8)	118 (42.9)	0 (0.0)	1,035 (42.6)	126 (37.7)	0 (0.0)
Male	597 (53.1)	92 (59.4)	0 (0.0)	308 (54.2)	59 (60.8)	0 (0.0)	764 (55.2)	157 (57.1)	3 (100)	1,396 (57.4)	208 (62.3)	1 (100)
Age, months												
Mean (SD)	2.6 (1.2)	2.6 (1.3)	0.0 (.)	8.6 (1.7)	8.5 (1.7)	10.0 (.)	17.3 (3.4)	17.3 (3.3)	19.0 (1.7)	40.2 (10.6)	40.3 (10.6)	27.0 (.)
Median (IQR)	2.0 (2.0-3.0)	3.0 (2.0-4.0)	0.0 (0.0-0.0)	9.0 (7.0-10.0)	9.0 (7.0-10.0)	10.0 (10.0- 10.0)	17.0 (14.0- 20.0)	17.0 (14.0- 20.0)	20.0 (17.0- 20.0)	40.0 (31.0- 49.0)	40.0 (31.0- 49.0)	27.0 (27.0- 27.0)
Season by year, n (%)												
2016 (May 2016 to April 2017)	255 (22.7)	0 (0.0)	0 (0.0)	108 (19.0)	0 (0.0)	0 (0.0)	276 (19.9)	0 (0.0)	0 (0.0)	485 (20.0)	0 (0.0)	0 (0.0)
2017 (May 2017 to April 2018)	303 (26.9)	0 (0.0)	0 (0.0)	174 (30.6)	0 (0.0)	0 (0.0)	396 (28.6)	0 (0.0)	0 (0.0)	804 (33.1)	0 (0.0)	0 (0.0)
2018 (May 2018 to April 2019)	423 (37.6)	0 (0.0)	0 (0.0)	186 (32.7)	0 (0.0)	0 (0.0)	490 (35.4)	0 (0.0)	0 (0.0)	796 (32.7)	0 (0.0)	0 (0.0)
2019 (May 2019 to April 2020)	144 (12.8)	152 (98.1)	0 (0.0)	100 (17.6)	94 (96.9)	0 (0.0)	222 (16.0)	269 (97.8)	0 (0.0)	346 (14.2)	333 (99.7)	0 (0.0)

	0	1	0	0	2	0	0	0	0	0	0
2020 (May to December)	(0.0)	(0.6)	(0.0)	(0.0)	(2.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	0	1	1	0	1	1	0	3	3	0	1
2021 (January to December)	(0.0)	(0.6)	(100)	(0.0)	(1.0)	(100)	(0.0)	(1.1)	(100)	(0.0)	(0.3)
	0	1	0	0	0	0	0	3	0	0	0
2022 (January to July)	(0.0)	(0.6)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(1.1)	(0.0)	(0.0)	(0.0)
Comorbidity during baseline period, n (%)											
Down syndrome	1 (0.1)	1 (0.6)	0 (0.0)	1 (0.2)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (0.2)	0 (0.0)	0 (0.0)
Congenital heart disease	23 (2.0)	1 (0.6)	0 (0.0)	16 (2.8)	4 (4.1)	0 (0.0)	13 (0.9)	2 (0.7)	0 (0.0)	8 (0.3)	1 (0.3)
Bronchopulmonary dysplasia	1 (0.1)	0 (0.0)	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Prematurity	19 (1.7)	3 (1.9)	0 (0.0)	16 (2.8)	6 (6.2)	0 (0.0)	1 (0.1)	1 (0.4)	0 (0.0)	1 (0.0)	0 (0.0)
Immunodeficiency	1 (0.1)	0 (0.0)	0 (0.0)	4 (0.7)	1 (1.0)	0 (0.0)	3 (0.2)	1 (0.4)	0 (0.0)	8 (0.3)	0 (0.0)
Pulmonary hypoplasia	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Airway stenosis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.1)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)
Esophageal atresia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Congenital metabolic disorder	1 (0.1)	0 (0.0)	0 (0.0)	4 (0.7)	0 (0.0)	0 (0.0)	11 (0.8)	2 (0.7)	0 (0.0)	25 (1.0)	0 (0.0)
Neuromuscular disorder	0 (0.0)	0 (0.0)	0 (0.0)	5 (0.9)	3 (3.1)	0 (0.0)	17 (1.2)	2 (0.7)	0 (0.0)	28 (1.2)	1 (0.3)

	0	0	0	0	0	0	0	0	0	0	0
Cystic fibrosis	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
No record of these comorbidities	1,082	150	1	529	85	1	1,339	269	3	2,367	332
	(96.2)	(96.8)	(100.0)	(93.1)	(87.6)	(100.0)	(96.7)	(97.8)	(100.0)	(97.4)	(99.4)
Palivizumab use, n (%)											
Yes	11	2	0	15	5	0	17	1	0	2	1
	(1.0)	(1.3)	(0.0)	(2.6)	(5.2)	(0.0)	(1.2)	(0.4)	(0.0)	(0.1)	(0.3)
No record of use	1,114	153	1	553	92	1	1,367	274	3	2,429	333
	(99.0)	(98.7)	(100)	(97.4)	(94.8)	(100)	(98.8)	(99.6)	(100)	(99.9)	(99.7)
Size of healthcare institution, n (%)											
Less than 200 beds	35	2	0	19	1	0	71	14	0	93	13
	(3.1)	(1.3)	(0.0)	(3.3)	(1.0)	(0.0)	(5.1)	(5.1)	(0.0)	(3.8)	(3.9)
200 to 499 beds	595	76	1	299	52	1	776	143	2	1,330	175
	(52.9)	(49.0)	(100)	(52.6)	(53.6)	(100)	(56.1)	(52.0)	(66.7)	(54.7)	(52.4)
500 or more beds	495	77	0	250	44	0	537	118	1	1,008	146
	(44.0)	(49.7)	(0.0)	(44.0)	(45.4)	(0.0)	(38.8)	(42.9)	(33.3)	(41.5)	(43.7)

Rounding may create totals slightly over or below 100% in some cases.